Elacestrant significantly improved progression-free survival and maintained a manageable safety profile, especially benefiting patients with ESR1-mutated tumors.

Mark Nestor reveals groundbreaking insights on botulinum toxin's evolving science, enhancing its efficacy and expanding its medical applications in dermatology.

Discover how botulinum toxin injections in the glabella affect brain function, enhancing mood by altering emotional feedback from frowning.

Expert discusses how, despite its importance, albuminuria screening remains underutilized, and improving adherence to dual testing can transform early CKD detection.

Exploration of the emergence of nonfactor treatment classes, explaining how these agents function independently of missing clotting factors and their relevance to patient convenience, dosing, and efficacy.

Among chemotherapy-naive patients, elacestrant extended median progression-free survival compared with standard therapy, particularly in ESR1-mutated cases.

The EMERALD study carries significant implications across multiple stakeholders in ER+/HER2- metastatic breast cancer.

Expert discusses how understanding and promoting awareness of CKD stages enables earlier intervention and better management of disease progression and cardiovascular risk.

A historical perspective on traditional factor replacement therapies, tracing their development, successes, and ongoing limitations such as short half-life, infusion requirements, and inhibitor formation.